These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35007989)

  • 1. Leveraging rAAV bioprocess understanding and next generation bioanalytics development.
    Escandell JM; Pais DA; Carvalho SB; Vincent K; Gomes-Alves P; Alves PM
    Curr Opin Biotechnol; 2022 Apr; 74():271-277. PubMed ID: 35007989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical challenges and advances in recombinant adeno-associated virus (rAAV) biomanufacturing.
    Fu Q; Polanco A; Lee YS; Yoon S
    Biotechnol Bioeng; 2023 Sep; 120(9):2601-2621. PubMed ID: 37126355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical methods to characterize recombinant adeno-associated virus vectors and the benefit of standardization and reference materials.
    Green EA; Lee KH
    Curr Opin Biotechnol; 2021 Oct; 71():65-76. PubMed ID: 34273809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular pathways of recombinant adeno-associated virus production for gene therapy.
    Sha S; Maloney AJ; Katsikis G; Nguyen TNT; Neufeld C; Wolfrum J; Barone PW; Springs SL; Manalis SR; Sinskey AJ; Braatz RD
    Biotechnol Adv; 2021; 49():107764. PubMed ID: 33957276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of the quality by design approach for gene therapy products: A case study for adeno-associated viral vectors.
    Tanaka T; Hanaoka H; Sakurai S
    Eur J Pharm Biopharm; 2020 Oct; 155():88-102. PubMed ID: 32784043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards a scalable bioprocess for rAAV production using a HeLa stable cell line.
    Escandell J; Moura F; Carvalho SB; Silva RJS; Correia R; Roldão A; Gomes-Alves P; Alves PM
    Biotechnol Bioeng; 2023 Sep; 120(9):2578-2587. PubMed ID: 37027346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in upstream process development for production of recombinant adeno-associated virus.
    Ou J; Tang Y; Xu J; Tucci J; Borys MC; Khetan A
    Biotechnol Bioeng; 2024 Jan; 121(1):53-70. PubMed ID: 37691172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rAAV2-producing yeast screening model to identify host proteins enhancing rAAV DNA replication and vector yield.
    Aponte-Ubillus JJ; Barajas D; Peltier J; Bardliving C; Shamlou P; Gold D
    Biotechnol Prog; 2019 Jan; 35(1):e2725. PubMed ID: 30298993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular design for recombinant adeno-associated virus (rAAV) vector production.
    Aponte-Ubillus JJ; Barajas D; Peltier J; Bardliving C; Shamlou P; Gold D
    Appl Microbiol Biotechnol; 2018 Feb; 102(3):1045-1054. PubMed ID: 29204900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-complementary and tyrosine-mutant rAAV vectors enhance transduction in cystic fibrosis bronchial epithelial cells.
    Lopes-Pacheco M; Kitoko JZ; Morales MM; Petrs-Silva H; Rocco PRM
    Exp Cell Res; 2018 Nov; 372(2):99-107. PubMed ID: 30244179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production and purification of recombinant adeno-associated vectors.
    Wang L; Blouin V; Brument N; Bello-Roufai M; Francois A
    Methods Mol Biol; 2011; 807():361-404. PubMed ID: 22034039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recombinant adeno-associated virus vector related impurities].
    Diao Y; Wang Q; Xiao W; Xu R
    Sheng Wu Gong Cheng Xue Bao; 2011 May; 27(5):717-23. PubMed ID: 21845838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy: challenges in cell culture scale-up.
    Shupe J; Zhang A; Odenwelder DC; Dobrowsky T
    Curr Opin Biotechnol; 2022 Jun; 75():102721. PubMed ID: 35398708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in scaling up AAV-based gene therapy manufacturing.
    Jiang Z; Dalby PA
    Trends Biotechnol; 2023 Oct; 41(10):1268-1281. PubMed ID: 37127491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism.
    Muzyczka N; Warrington KH
    Hum Gene Ther; 2005 Apr; 16(4):408-16. PubMed ID: 15871672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herpes simplex virus clearance during purification of a recombinant adeno-associated virus serotype 1 vector.
    Ye GJ; Scotti MM; Thomas DL; Wang L; Knop DR; Chulay JD
    Hum Gene Ther Clin Dev; 2014 Dec; 25(4):212-7. PubMed ID: 25357151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ubiquitination of recombinant adeno-associated viral vector and its application].
    Wang QZ; Lu YH; Diao Y; Xu RA
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 41(5):586-91. PubMed ID: 23086655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. rAAV vector-mediated gene therapy for experimental ischemic stroke.
    Li ZJ; Wang RZ
    Neurol India; 2008; 56(2):116-21. PubMed ID: 18688133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bound Protein- and Peptide-Based Strategies for Adeno-Associated Virus Vector-Mediated Gene Therapy: Where Do We Stand Now?
    Zhang X; Chai Z; Samulski RJ; Li C
    Hum Gene Ther; 2020 Nov; 31(21-22):1146-1154. PubMed ID: 32940063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production of recombinant adeno-associated virus vectors.
    Zolotukhin S
    Hum Gene Ther; 2005 May; 16(5):551-7. PubMed ID: 15916480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.